Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843047 · ClinicalTrials.gov registry record · NA
Electronic Cigarette Unit Price Manipulations in the Experimental Tobacco Marketplace
A NA study, sponsored by Virginia Polytechnic Institute and State University.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT03843047: Completed NA study, sponsored by Virginia Polytechnic Institute and State University.
NCT03843047 is a NA study that has completed, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03843047, a NA study, has completed, sponsored by Virginia Polytechnic Institute and State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
Electronic cigarettes (e-cigarettes) may be a safer alternative to conventional cigarettes and are available in a broad range of nicotine strengths. The overall goal of this project is to use an experimental analogue of the real-world tobacco marketplace to examine the effects of nicotine strength on e-cigarette consumption and the likelihood that current smokers will either switch to e-cigarettes (which may reduce harm) or use both products in combination (which may increase harm). Testing effects of e-cigarette nicotine strength under controlled conditions in a context that models the real world will facilitate evidence-based policies that have a net benefit to health.
Primary Outcome
The degree to which various e-liquid nicotine strengths (3, 6, 12, 24 mg/mL) substitute for conventional cigarettes will be assessed.
Interventions
- DRUG 3 mg/mL nicotine strength e-liquid
- DRUG 6 mg/mL nicotine strength e-liquid
- DRUG 12 mg/mL nicotine strength e-liquid
- DRUG 24 mg/mL nicotine strength e-liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
What the finished NCT03843047 record still lists
NCT03843047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which 3 mg/mL nicotine strength e-liquid is the first listed.
NCT03843047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03843047 about?
NCT03843047 is a clinical study titled "Electronic Cigarette Unit Price Manipulations in the Experimental Tobacco Marketplace". Electronic cigarettes (e-cigarettes) may be a safer alternative to conventional cigarettes and are available in a broad range of nicotine strengths. The overall goal of this project is to use an experimental analogue of the real-world tobacco marketplace to examine the effects of nicotine strength o...
What is the current status of trial NCT03843047?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2019-03-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT03843047?
The interventions under investigation include: 3 mg/mL nicotine strength e-liquid (DRUG), 6 mg/mL nicotine strength e-liquid (DRUG), 12 mg/mL nicotine strength e-liquid (DRUG), 24 mg/mL nicotine strength e-liquid (DRUG).
Who is sponsoring clinical trial NCT03843047?
This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03843047's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI